Article
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation.
BMC cancer - 9 Dec 2022
Kato Taigo, Matsubara Nobuaki, Shiota Masaki, Eto Masatoshi, Osawa Takahiro, Abe Takashige, Shinohara Nobuo, Yasumizu Yota, Tanaka Nobuyuki, Oya Mototsugu, Nishimoto Koshiro, Hayashi Takuji, Nakayama Masashi, Kojima Takahiro, Namikawa Kenjiro, Fujisawa Takao, Okano Susumu, Hida Eisuke, Nakamura Yoshiaki, Bando Hideaki, Yoshino Takayuki, Nonomura Norio
Abstract excerpt
BACKGROUND: Previous clinical trials have demonstrated the potential efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) in patients with cancer involving homologous recombination repair (HRR) gene-mutation. Moreover, HRR gene-mutated cancers are effectively treated with immune checkpoint inhibitors (ICIs) with the increase in tumor mutation burden. We have proposed to conduct a multicenter,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.